| Mental Retardation |
2010-021384-33: The Effect of Naltrexone in Amphetamine Dependence: A Study using Functional Magnetic Resonance Imaging |
|
|
| Ongoing | 2 | 70 | Europe | Tablet, Naltrexon | Beroendecentrum Stockholm, Swedish Brain Fund, Märta Lundqvists stiftelse | Amphetamine dependence, Amphetamine dependence, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2011-003071-11: Cognitieve en emotionele controle: Gelijkenissen en verschillen in neuraal substraat - 11C-Raclopride Cognitieve en emotionele controle: Gelijkenissen en verschillen in neuraal substraat - 11C-Raclopride |
|
|
| Ongoing | 2 | 30 | Europe | 11C Raclopride, Solution for injection | Ghent University, Ghent University | Healthy volunteers, Healthy volunteers Gezonde vrijwilligers, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2011-003313-42: Agomelatine efficacy of the drug to improve sleep problems in autistic people Eficacia del fármaco agomelatina para mejorar los problemas del sueño en personas autistas |
|
|
| Ongoing | 2 | 40 | Europe | Agomelatine, Tablet, Valdoxan 25mg | Hospital General Universitario de Alicante, Hospital General Universitario de Alicante | The treatment of sleep disorders in patients with autism spectrum disorders (ASD) El tratamiento de los trastornos del sueño en los pacientes con trastornos del espectro autista (TEA), The treatment of sleep problems in autistic patients El tratamiento de los problemas del sueño en los pacientes autistas, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2011-006099-38: Effects of an antiandrogenic oral contraceptive on eating behaviour in women with bulimia |
|
|
| Ongoing | 2 | 100 | Europe | Capsule, Yasmin | Karolinska University Hospital, Karolinska University Hospital | Bulimia nervosa is an eating disorder with a prevalence of about 2% in young women (Fairburn and Beglin, 1990). It is characterized by frequent binge eating episodes and the regular use of inappropriate compensatory behaviours, such as self-induced vomiting, laxative abuse or periods of fasting to prevent increase in body weight., Bulimia is an eating disorder. Those who suffer from the disease binge and compensates by throwing up food, laxatives, engage in excessive exercise and / or use of diet pills. Bulimia är en ätstörning. Den som lider av sjukdomen hetsäter och kompenserar genom att kräkas upp maten, använda laxermedel, ägna sig åt överdriven motion eller/och använda sig av bantningspreparat., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2012-002692-34: Clinical study for the assessment of safety and efficacy of Bezafibrate as a drug therapy for patients suffering from an inborn muscular dysfunction characterized by intramuscular lack of energy supply Klinische Studie zum Nachweis der Sicherheit und Wirksamkeit von Bezafibrat als Arzneimitteltherapie für Patienten mit angeborener Muskelerkrankung, die zu einer gestörten Energiebereitstellung der Muskulatur führt |
|
|
| Ongoing | 2 | 16 | Europe | Bezastad, Coated tablet, Bezastad | Univ.-Klinik für Kinder- und Jugendheilkunde, Univ.-Klinik für Kinder- und Jugendheilkunde | mitochondrial disorder Genetisch bedingte mitochondriale Muskelerkrankungen, Inborn mitochondrial diseases leading to an abberant energy supply in muscular tissue severly affecting muscular performance and sometimes leading to psycho-mental disability and breathing failure Genetische mitochondriale Erkrankung,die zu einer gestörten intramuskulären Energiebereitstellung führt. Folgen: Leistungsintoleranz bis zu psychomentaler Behinderung und Versagen der Atemmuskulatur, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2014-000647-32: A medical treatment trial investigating whether degarelix decreases the risk of persons with pedophilic disorder from committing sexual child molestation |
|
|
| Ongoing | 2 | 60 | Europe | Powder and solution for solution for injection, FIRMAGON | Karolinska University Hospital, Karolinska University Hospital | Pedophilia acccording to DSM-5 (F65.4), Men suffering from pedophilia, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2013-003196-35: Assessing the subjective intensity of oral psilocybin in patients with treatment-resistant depression |
|
|
| Ongoing | 2 | 12 | Europe | Psilocybin, Psilocybin, Capsule | Imperial College London | Major depressive disorder, Pervasive and persistent low mood that is accompanied by low self-esteem and by a loss of interest or pleasure in normally enjoyable activities., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2015-001456-29: A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD) Eine doppelt-verblindete, placebo-kontrollierte, randomisierte, mulitzentrische Studie zur Überprüfung der Wirksamkeit einer Minocyclinaugmentation bei Patienten mit therapierefraktärer unipolarer depressiver Erkrankung |
|
|
| Ongoing | 2 | 160 | Europe | Minocycline, Capsule, hard, Udima | Charité - Universitätsmedizin Berlin, Bundeministerium für Bildung und Forschung (BMBF) | Minocycline, a broad-spectrum and central nervous system entering tetracycline, reduces within an additional therapy the symptomatology of depressive patients. Minocyclin, ein pleiotropes, ZNS-gängiges Tetrazyklin, reduziert im Rahmen einer Begleittherapie die Symptomatik von depressiven Patienten. Ursächlich hierfür ist u.a. eine anti-inflammatorische sowie neuroprotektive Wirkung., Minocycline, a broad-spectrum and central nervous system entering tetracycline, reduces within an additional therapy the symptomatology of depressive patients. Minocyclin, ein Tetrazyklin, reduziert im Rahmen einer Begleittherapie die Symptomatik von depressiven Patienten durch u.a. seine anti-inflammatorische sowie neuroprotektive Wirkung., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2014-001541-24: Neuroenhancement of Interpersonal Psychotherapy in Major Depression Augmentation von Interpersoneller Psychotherapie durch D-Cycloserin |
|
|
| Ongoing | 2 | 28 | Europe | Cycloserin-Kapseln, Capsule, hard, Cycloserine | University Medical Center Freiburg, University Medical Center Freiburg | Major Depression (ICD-10; F32.2/F33.2) Depressive Störung (ICD-10; F32.2/F33.2), Disorder in which the fundamental disturbances are a change in affect or mood to depression and a usually accompanied change in the overall level of activity. Störung deren Hauptsymptome eine Veränderung der Stimmung oder der Affektivität zur Depression hin und eine Veränderung des allgemeinen Aktivitätsniveaus sind., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 2 | 54 | Europe | Bocouture (Botulinumtoxin A), Powder for solution for injection, Bocouture | Medizinische Hochschule Hannover, Asklepios Klinik Nord, Medizinische Hochschule Hannover | Borderline personality disorder Borderline-Persönlichkeitsstörung, n.a., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2014-000420-15: Detoxification of high dose Benzo with flumazenil infusion Ontgifting van hoge dosis Benzo's door middel van een infuus met flumazenil |
|
|
| Ongoing | 2 | 30 | Europe | Anexate, Solution for injection, Anexate | Radboud University Medical Centre, department of Psychiatry, Radboud University Medical Centre, department of Psychiatry, Nijmegen Institute for Scientist Practitioners in Addiction (NISPA), Novadic-Kentron Addiction Care network | Patients diagnosed with benzodiazepine dependence with an average daily dose of at least 30 mg of diazepam equivalence., Patients with high dose benzodiazepine dependence who cannot succeed in detoxification otherwise, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 2 | 90 | Europe | bumetanide oral solution 0.5mg/ml, Syrup | Brain Center Rudolf Magnus, University Medical Center Utrecht, Department of Psychiatry, Utrecht , the Netherlands, ZonMW | Autism Spectrum Disorder, Autism, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2015-000465-31: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression Eine 8-wöchige, randomisierte, doppelblinde, placebo-kontrollierte klinische Studie mit Cannabidiol als Add-on-Therapie zur Behandlung der bipolaren Depression |
|
|
| Ongoing | 2 | 126 | Europe | Cannabidiol, CBD, Capsule, hard | Charité - Universitätsmedizin Berlin, Charité - Universitätsmedizin Berlin | Bipolar disorder, current episode depressed Bipolare affektive Störung, gegenwärtig depressive Episode, Bipolar disorder, current episode depressed aktuelle depressive Episode bei einer Bipolaren Störung, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-001719-19: Can a selective progesterone receptor modulator be used for treatment of premenstrual dysphoric disorder? Kan en selektiv progesteronreceptor-modulerare användas för behandling av premenstruell dysfori? |
|
|
| Ongoing | 2 | 100 | Europe | esmya, Tablet, Esmya | Uppsala University, Uppsala University | Premenstrual dysphoric disorder Premenstruell dysfori, Premenstrual dysphoric disorder Premenstruell dysfori, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 2 | 120 | Europe | Infusion, Ketamine (Ketalar by Pfizer) | UZ Leuven, IWT Agentschap voor Innovatie door Wetenschap en Technologie | Major depressive disorder and Bipolar Disorder I and II, depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Not yet recruiting | 2 | 172 | Europe | bumetanide, bumetanide, Tablet, Bumetanide | UMC Utrecht, Dutch Brain Foundation | Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Epilepsy, Autism, ADHD, Epilepsy, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2015-004527-32: Sitagliptin is an established diabetes drug medication that acts primarily by stimulating the body’s ability to release insulin, leading to a lowering of blood sugar levels. This clinical trial will examine whether treatment with Sitagliptin can improve both depression and type 2 diabetes together |
|
|
| Ongoing | 2 | 60 | Europe | Januvia (Sitagliptin), Capsule, hard, Januvia (Sitagliptin) | King's College London, Kings College Hospital NHS Foundation Trust, KHP BRC Experimental Medicine Pilot Project Award | Depression in type 2 diabetes, Depression in type 2 diabetes, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-001567-37: Efficacy of dexmedetomidine for conscious sedation during dental treatement of uncooperative patients with intellectual disability and fear of dentists. |
|
|
| Ongoing | 2 | 30 | Europe | Solution for injection, Dexdor | University Medical Center Groningen, University medical Center Gronignen | dentophobia intellectual disability, Fear of dentist Intellectual disability, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 2 | 70 | Europe | Tablet, Madopark Quick | Aging Research Center, Karolinska Institutet and Stockholm University, European Research Council | No medical condition is under investigation. The project investigates normal age-related decline in intellectual abilities., No medical condition is under investigation. The project investigates normal age-related decline in intellectual abilities., Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2016-002068-14: Investigation of antidepressant efficacy of oral ketamine treatment |
|
|
| Ongoing | 2 | 60 | Europe | Solution for injection/infusion, Ketamin-hameln, Dormicum | Medical University of Vienna, Medical University of Vienna | Major depressive episode (Major depressive disorder, Biploar disorder), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-000118-31: A trial to investigate the efficacy and safety of immunotherapy (intravenous immunoglobulins and rituximab) in patients with antibody-associated psychosis, compared to placebo (SINAPPS2) |
|
|
| Ongoing | 2 | 80 | Europe | IVIG, Rituximab, Solution for infusion, IVIG, Rituximab | Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, Medical Research Council | Antibody associated Psychosis, Cases of psychosis that are likely caused by the presence of antibodies that affect the brain, found in the blood., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 2 | 30 | Europe | Syntocinon, N.A., Nasal spray, solution, Syntocinon | AZIENDA OSPEDALIERA G. BROTZU, Fondazione Banco di Sardegna | Autism Spectrum Disorder Disturbo dello Spettro Autistico, Is a condition charaterized by abnormalities in the domains of communication and socialization and by a restricted and repetitive pattern of interests and activities. E' una condizione clinica caratterizzata da anomalie nei settori della comunicazione e della socializzazione e da attivit¿ ridotte e ripetitive., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 2 | 20 | Europe | bumetanide, bumetanide, Tablet, bumetanide | UMC Utrecht, Stichting Michelle | Tuberous Sclerosis Complex, Tuberous Sclerosis Complex, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-003343-11: Does stimulation of the receptor for Glucagon-like Peptide 1 (GLP-1) reduce alcohol intake in patients with alcohol dependence? |
|
|
| Ongoing | 2 | 139 | Europe | Powder and solvent for solution for injection in pre-filled pen, Bydureon | Psychiatric Centre Copenhagen, Region Hovedstadens Forskningsfond, Region Hovedstadens Psykiatri, Fonden Novaví | Alcohol dependence, Alcohol dependence, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Not yet recruiting | 2 | 60 | Europe | SPI-1005, Ebselen, NA, Capsule | University of Oxford, The Stanley Medical Research Institute | Patients with bipolar disorder meeting DSM-5 criteria for hypomania or mania, Bipolar disorder is characterised by periods of elevated mood and periods of depression. The elevated mood is known as hypomania or mania: an individual feels abnormally happy, energetic or irritable., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-001739-38: A study to evaluate the safety and tolerability of TAK-831 in patients with schizophrenia. |
|
|
| Not yet recruiting | 2 | 32 | Europe | TAK-831, Tablet | Takeda Development Centre Europe Ltd., Takeda Development Centre Europe Ltd. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-000645-48: Cystadane in the treatment of AGU Cystadane AGU-taudin hoidossa |
|
|
| Ongoing | 2 | 15 | Europe | Oral powder, Cystadane anhydrous | Minna Laine, Prof. Ritva Tikkanen, Orphan Europe SARL | Aspartylglucosaminuria Aspartyyliglukosaminuria, Aspartylglucosaminuria (AGU) is a progressive disease that results in severe mental retardation of the patients. The main symptom of the disease is the progressive loss of mental capabilities. Aspartyyliglukosaminuria (AGU) on vaikeaa kehitysvammaisuutta aiheuttava, etenevä lastenneurologinen tauti. Taudin pääoire on henkisen kehityksen taantuminen., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
2017-001357-14: Randomized, doubleblind, 4-arms, monocentric, interventinal Study for enhancing the efficacy of tDCS across from single intervention or Placebo by nicotinergic stimulation in schizophrenia. Verbesserung der klinischen Effekte der tDCS durch nikotinerger Stimulation bei Patienten mit einer Schizophrenie |
|
|
| Ongoing | 2 | 60 | Europe | Champix, Capsule, hard, Champix | Klinikum der Universität München - AöR verteten durch den Vorstand des Bereiches Humanmedizin, Deutsche Forschungsgemeinschaft (DFG) Förderkennzeichen HA 6091/5-1 | Schizophrenia Schizophrenie, Schizophrenia Schizophrenie, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-001490-16: Treatment of Bulimia Nervosa, with and without simultaneous probable ADHD, with the stimulant medicine Lisdexamphetamin . Behandling av Bulimia Nervosa, med och utan samtidig sannolik ADHD, med den psykostimulerande medicinen Lisdexamfetamin. |
|
|
| Ongoing | 2 | 50 | Europe | Capsule, hard, Elvanse vuxen | Stockholms läns landsting, Stiftelsen Söderström-Königska sjukhemmet, Petrus och Augusta Hedlunds stiftelse | Bulimia Nervosa with and without simultaneous Attention Deficit Hyperactivity Disorder. Bulimia Nervosa med och utan samtidig Attention Deficit Hyperactivity Disorder., Bulimia Nervosa with and without simultaneous ADHD Bulimia Nervosa med och utan samtidig ADHD, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-004973-42: This study tests whether BI 409306 prevents patients with a specific type of mental illness (attenuated psychosis syndrome) from becoming worse. This study looks at how well patients tolerate the medicine and how safe and effective it is over 1 year. |
|
|
| Not yet recruiting | 2 | 300 | Europe | BI 409306, BI 409306, Film-coated tablet | Boehringer Ingelheim Limited, Boehringer Ingelheim Limited | attenuated psychosis syndrome, attenuated psychosis syndrome, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-002232-16: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects with Treatment-Resistant Depression |
|
|
| Not yet recruiting | 2 | 90 | Europe | TAK-653, TAK-653, Tablet | Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd | Treatment Resistant Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-004710-95: Extended-release injectable suspension naltrexone (XR-NTX) as an adjunct pharmacotherapy for prevention of drug use in patients with substance use disorder in treatment for ADHD |
|
|
| Not yet recruiting | 2 | 128 | Europe | Naltrexone, Injection, vivitrol | Beroendecentrum Stockholm, Beroendecentrum Stockholm, Alkermes, Swedish research council, Swedish research council for health, working life and welfare | Amphetamine dependence and ADHD (Attention-Deficit/Hyperactivity Disorder), Patients who fulfil DSMIV/5 criteria for amphetamine dependence and ADHD (Attention-Deficit/Hyperactivity Disorder), respectively, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 2 | 30 | Europe | Injection, Tiacur® | Dept of Psychiatry, Umeå University Hospital, Västerbotten county council, Umeå University | Patients with Anorexia Nervosa and Healthy Controls, Anorexia Nervosa, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 2 | 66 | Europe | Solution for injection in pre-filled syringe, RoActemra | Linköping University, Region Östergötland | Major depressive disorder, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-000445-39: A study comparing the safety and clinical effects of different formulations of a new vaccine, ACI-24 with placebo in patients with mild Alzheimer's disease |
|
|
| Ongoing | 2 | 45 | Europe | ACI-24, ACI-24, Suspension for injection | AC Immune SA, AC Immune SA | Alzheimer's Disease, Alzheimer's Disease, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2013-002996-16: ANRS SHS155 STIMAGO: Pilote study to evaluate the benefits and the risks of methylphenidate for the treatment of cocain dependence. ANRS SHS155 STIMAGO : Etude pilote pour l’évaluation des bénéfices et des risques du méthylphénidate pour la prise en charge de la dépendance à la cocaïne. |
|
|
| Not yet recruiting | 2 | 20 | Europe | Prolonged-release tablet, Concerta LP 18 mg | Inserm-ANRS, ANRS | Cocaine dependence Dépendance à la cocaïne, Cocaine dependence Dépendance à la cocaïne, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-001212-30: A trial to study effects of a single dose Citalopram on emotion processing in patients with Borderline Personality Disorder and the associated modulation of fMRI BOLD signals |
|
|
| Ongoing | 2 | 30 | Europe | Film-coated tablet, Citalopram | Central Institute of Mental Health, represented by commercial and administrative Director, Boehringer Ingelheim Pharma GmbH & Co KG | Borderline Personality Disorder, Borderline Personality Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2015-004745-70: Efficacy of ketamine nose-spray on acute suicidal thoughts and behaviour Effectiviteit van ketamine-neusspray op acute suïcidale gedachten en gedrag |
|
|
| Ongoing | 2 | 128 | Europe | ketalar, Nasal spray, solution in single-dose container, Ketalar | Academic Medical Center (AMC), Academic Medical Center | Acute suicidality, which is a rapid increase in suicidal ideation or behaviour from the patient's 'baseline' in the last 24 hours. Acute suïcidaliteit, gedefinieerd als een snelle toename in suïcidale gedachten of gedrag vanaf de 'baseline' van patiënt., Acute suicidality, thoughts about the wish to kill oneself, or behaviour with either the aim to die or a significant likelyhood that one could die because of this behaviour. Acute suïcidaliteit, gedachten over de wens zichzelf van het leven te willen beroven, of gedrag met het doel te sterven of met een grote waarschijnlijkheid dat men als gevolg van het gedrag sterft, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-001166-42: Clinical research study to determine how "trazodone" can influence the sleep and how it works in the body after one or repeated doses taken by mouth, in children suffering from insomnia and with autism, intellectual disability or attention deficit hyperactivity disorder (ADHD) Estudio de investigación clínica para evaluar cómo puede influir la trazodona sobre el sueño, así como su funcionamiento en el cuerpo tras una o varias dosis tomadas por boca, en niños que sufran insomnio y autismo, discapacidad intelectual o trastorno por déficit de atención con hiperactividad (TDAH) |
|
|
| Ongoing | 2 | 36 | Europe | trazodone hydrochloride, 152PO17433, Oral drops, solution | Aziende Chimiche Riunite Angelini Francesco ACRAF S.p.A (Angelini S.p.A.), AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A., Aziende Chimiche Riunite Angelini Francesco ACRAF S.p.A (Angelini S.p.A.), AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. | Insomnia in children and adolescents with autism, intellectual disability or ADHD Insomnio en niños y adolescentes, con autismo, discapacidad intelectual o TDAH, Insomnia in children and adolescents with autism, intellectual disability or ADHD Insomnio en niños y adolescentes, con autismo, discapacidad intelectual o TDAH, Diseases [C] - Nervous System Diseases [C10] | | | | |
2017-004823-66: Early-life stress, the endocannabinoid system, and fear memory extinction |
|
|
| Ongoing | 2 | 48 | Europe | Namisol, Hydrocortison CF, ECP002A, RVG 50730, Tablet, Hydrocortison CF | Radboudumc, Radboudumc | healthy volunteers gezonde vrijwilligers, intended indication: posttraumatic stress disorder (PTSD) beoogde indicatie: posttraumatic stress disorder (PTSD), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-004618-17: Immunological treatment for Schizophrenia Immunologisk behandling av schizofreni |
|
|
| Not yet recruiting | 2 | 12 | Europe | MabThera, Concentrate for solution for infusion, MabThera | Region Örebro län, Region Örebro län | Treatment-resistant patients with schizophrenia spectrum disorder (SSD), Treatment-resistant patients with schizophrenia spectrum disorder (SSD), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-004619-28: Immunological treatment of Obsessive-Compulsive Disorder Immunologisk behandling av tvångssyndrom |
|
|
| Not yet recruiting | 2 | 12 | Europe | MabThera, Concentrate for solution for infusion, MabThera | Region Örebro län, Region Örebro län | Treatment-resistant patients with Obsessive Compulsive Disorder (OCD), Treatment-resistant patients with Obsessive Compulsive Disorder (OCD), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-001884-21: Antidepressant trial of a novel P2X7 receptor blocker JNJ-54175446. |
|
|
| Not yet recruiting | 2 | 142 | Europe | JNJ-54175446, JNJ-54175446, Capsule, hard | Cambridgeshire and Peterborough NHS Foundation Trust and University of Cambridge, Wellcome Trust, Janssen Pharmaceutica NV | Major depressive disorder with an incomplete response to monoaminergic antidepressants and with biomarker profile indicative of inflammation, People with: - major depressive disorder whose condition has not improved with the current antidepressant medications.- increased levels of inflammation., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-000014-38: A Phase IIa Study to Determine the Safety, Tolerability and Efficacy of a daily oral dose of THX-110 in Adult Patients with Tourette Syndrome (TS) |
|
|
| Not yet recruiting | 2 | 60 | Europe | THX-110 [Dronabinol], THX-110 [PEA (Palmitoylethanolamide)], Capsule, soft, Tablet, Dronabinol Capsules, USP | Therapix Biosciences Ltd., Therapix Biosciences Ltd. | Tourette Syndrome, Neuropsychiatric disorder characterized by multiple motor or vocal tics., Diseases [C] - Nervous System Diseases [C10] | | | | |
| Not yet recruiting | 2 | 130 | Europe | Cannabidiol, Capsule, Film-coated tablet, Risperidon Actavis | Mental Health Center Glostrup, The Benzon Foundation, Mental Health Center Glostrup | Non-affective psychosis and lifetime cannabis use, Patients affected by both psychosis and lifetime cannabis use, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-001683-29: A study to explore the efficacy JNJ-61393215 in the treatment of depression |
|
|
| Not yet recruiting | 2 | 218 | Europe | JNJ-61393215, 45-mg, Capsule, hard | Janssen-Cilag International NV, Janssen Research and Development, LLC | Adjunctive Treatment in Adults with Major Depressive Disorder with Anxious Distress with Suboptimal Response to Standard Antidepressants, Major depression with anxiety, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-001696-36: Study of efficacy of low-dose interleukin-2 in alteration of the immune system associated with depression Studio di efficacia dell’interleuchina-2 a basso dosaggio nelle alterazioni del sistema immunitario associate alla depressione |
|
|
| Not yet recruiting | 2 | 36 | Europe | Aldesleuchina, [Aldesleuchina], Powder for solution for injection | OSPEDALE SAN RAFFAELE, Unione Europea H2020 –SCI 2016-2017 | Depressive episode in course of mood disorder Episodio depressivo in corso di disturbo dell’umore, Depressive episode in course of mood disorder Episodio depressivo in corso di disturbo dell’umore, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-001084-20: An experimental trial to investigate a new medicine (drug), TAK-041, in patients with schizophrenia |
|
|
| Not yet recruiting | 2 | 32 | Europe | TAK-041, Powder for oral suspension | Takeda Development Centre Europe Ltd., Takeda Development Centre Europe Ltd. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-003112-39: A Clinical Trial of Scopolamine Versus Placebo for Individuals with Bipolar Disorder who are Experiencing a Depressive Episode (SCOPE-BD) |
|
|
| Not yet recruiting | 2 | 60 | Europe | Scopolamine (Hyoscine Hydrobromide), Solution for injection/infusion, Scopolamine (Hyoscine Hydrobromide) | National University of ireland Galway, Stanley Medical Research Institute | Bipolar Disorder, Bipolar Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-002947-27: Simvastatin add-on to Escitalopram in patients with obesity and depression Simvastatin als Zusatztherapie zur antidepressiven Medikation mit Escitalopram bei Patienten mit Depression und Adipositas |
|
|
| Not yet recruiting | 2 | 160 | Europe | SimvaHEXAL®, ESCITALOPRAM, Capsule, hard, Film-coated tablet, SimvaHEXAL® | Charité – Universitätsmedizin Berlin, Charité – Universitätsmedizin Berlin | Patients with comorbid obesity (body mass index ≥ 30) and major depression Patienten mit komorbider Adipositas (body mass index ≥ 30) und Major Depression, Patients with obesity and depression Patienten mit starkem Übergewicht und Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-002106-52: CANnabidiol for Behavioural Symptoms in Alzheimer’s Disease |
|
|
| Not yet recruiting | 2 | 40 | Europe | Cannabidiol, Capsule, hard | King's College London, South London and Maudsley NHS Foundation Trust, King's Health Partner's R&D Challenge Funds, Psychiatric Research Trust, Rosetrees' Trust | Alzheimer's disease patients with BPSD, Alzheimer's disease patients with behavioural and psychological symptoms e.g. anxiety, agitation, hallucinations and delusions, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2019-001408-39: Treating Anxiety to PrevEnt Relapse in Psychosis (TAPERS): a feasibility trial |
|
|
| Not yet recruiting | 2 | 40 | Europe | Sertraline, Tablet, Sertraline | Cardiff University, Welsh Government | Psychosis, Psychosis is a medical term used to describe hearing or seeing things that do not exist, or believing things that other people do not., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-000695-41: A clinical study to explore the efficacy of JNJ-67953964 in the treatment of depression |
|
|
| Not yet recruiting | 2 | 180 | Europe | JNJ-67953964-AAA, Capsule | Janssen-Cilag International NV, Janssen Research and Development LLC | Major Depressive Disorder, depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-004054-28: Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study |
|
|
| Not yet recruiting | 2 | 20 | Europe | Psilocybin, NA, Capsule, soft | Imperial College London | Anorexia Nervosa, Anorexia Nervosa, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-004480-31: Antidepressant effects of psilocybin in pharmaco-resistant depression Psilocybin versus ketamin v terapii rezistentní deprese |
|
|
| Not yet recruiting | 2 | 60 | RoW | PSILOCYBIN, KETAMINE, MIDAZOLAM, D0000407, K1350, Capsule | Národní ústav duševního zdraví, Národní ústav duševního zdraví | The study will include 60 patients with pharmaco-resistant depression (30 male, 30 female, aged 18–65). The basic inclusion criterion is the diagnosis of pharmaco-resistant moderate to severe depressive episode (F32.1–2, F33.1–2) without psychotic symptoms as per ICD-10 criteria with a MADRS score over 20 and excluding patinets with MADRS suicidality score (item 10) more than 4. Do studie bude zařazeno 60 pacientů s farmakorezistentní depresí (30 mužů, 30 žen, věk 18-65). Základním vstupním kritériem je diagnóza farmakorezistentní deprese středně těžké až těžké epizody (F32.1–2, F33.1–2) bez psychotických příznaků dle MKN-10 kritérií a skóre MADRS nad 20 bodů, nezahrnující pacienty s MADRS skóre suicidality (položka 10) více než 4., The study will include 60 patients with pharmaco-resistant depression (30 male, 30 female, aged 18–65). Studie bude probíhat na 60ti pacientech s farmakorezistentní depresí (30 mužů, 30 žen, věk 18-65)., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-002708-15: Flexible-dose Long-term Extension Study of Lu AF11167 in Patients WithSchizophrenia With Prominent Negative Symptoms |
|
|
| Not yet recruiting | 2 | 240 | Europe, RoW | Lu AF11167 modified-release tablet, Modified-release tablet | H. Lundbeck A/S, H. Lundbeck A/S | schizophrenia with persistent prominent negative symptoms, schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003573-97: A Trial of Psilocybin in Clinical Depression Resistant to Standard Treatments |
|
|
| Not yet recruiting | 2 | 60 | Europe | Psilocybin, Capsule | King's College London, South London & Maudsley NHS Foundation Trust, National Institute for Health Research Clinician Scientist Fellowship Programme (CS-2017-17-007) | Major depressive disorder, Clinical depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-004255-36: Cesar - an open, randomized controlled phase II study, comparing Naltrexon and Fluoxetin treating Compulsive Sexual Behavior Disorder. Cesar - en öppen randomiserad kontrollerad fas II-studie som jämför Naltrexon med Fluoxetin vid behandling av tvångsmässig sexuell beteendestörning. |
|
|
| Not yet recruiting | 2 | 80 | Europe | Fluoxetine Orion, Tablet, Capsule, hard, Naltrexon Vitaflo 50 mg, tablets for oral treatment., Fluoxetine Orion | Karolinska Universitetssjukhuset, SLSO, Region Västerbotten | Compulsive Sexual Behavior Disorder Tvångsmässig sexualitet/sexuell störning., Compulsive Sexual Behavior Disorder Tvångsmässig sexualitet/sexuell störning., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003816-38: Add-on buprenorphine for the treatment of severe suicidal ideas Traitement des idées suicidaires sévères par adjonction de buprénorphine |
|
|
| Not yet recruiting | 2 | 180 | Europe | BUPRENORPHINE MYLAN 0.4MG, BUPRENORPHINE MYLAN 0.8MG, Sublingual tablet, BUPRENOPRPHINE MYLAN 0.4MG | CHU DE NIMES, CHU DE NIMES | Treatment of severe suicidal ideas in patients suffers from a current major depressive episode Traitement des idées suicidaires chez les patients souffrant de depression caractérisée, Treatment of severe suicidal ideation in patients with major depression Traitement des idées suicidaires chez les patients avec depression caractérisée, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-002196-35: Bumetanide for developmental disorders Bumetanide bij ontwikkelingsstoornissen |
|
|
| Ongoing | 2 | 75 | Europe | Bumetanide, Tablet, Bumetanide | | Neurodevelopmental disordersAutism spectrum disorderLearning disordersIntellectual disabilityAttention deficit hyperactive disorder, developmental disordersautismADHDlearning problems, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-003984-24: Efficacy and safety of psilocybin in treatment-resistant major depression Wirksamkeit und Sicherheit von Psilocybin bei therapieresistenter unipolarer Depression |
|
|
| Not yet recruiting | 2 | 144 | Europe | Psilocybin 25 mg, Psilocybin 5 mg, Nicotinamide, Psilocybin25, Psilocybin5, Nicotinamide, Capsule | Central Institute of Mental Health, Bundesministerium für Bildung und Forschung (BMBF) | Treatment-Resistant Depressive Episode or Treatment-Resistant Recurrent Depressive Disorder of moderate to severe degree withoutpsychotic features, Treatment-resistant major depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000829-55: Can a single dose of psilocybin reduce alcohol intake in patients with alcohol use disorder? |
|
|
| Not yet recruiting | 2 | 100 | Europe | PEX010 (Psilocybin Capsules 25mg), PEX010, Capsule | Psychiatric Centre Copenhagen, The Novo Nordic Foundation, The Lundbeck Foundation, The Ivan Nielsen Foundation | Alcohol Use Disorder, Alcohol dependence, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000094-24: A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia |
|
|
| Ongoing | 2 | 576 | Europe, RoW | Risperidone, MK-8189, Tablet, Capsule, Risperdal (Risperdione) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-001621-27: A study on ketamine as a treatment for depression and demoralization in patients with advanced cancer Een studie naar het effect van ketamine als behandeling voor depressie en demoralisatie bij patiënten met gevorderde kanker |
|
|
| Not yet recruiting | 2 | 10 | Europe | Solution for injection, Ketanest-S | University Medical Center Groningen, University Medical Center Groningen | Major depressive disorder Depressie, Depression Depressie, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-001692-37: Pharmacologic treatment augmentation in chronic depressionrandomized, controlled, double blinded, phase II study |
|
|
| Not yet recruiting | 2 | 60 | Europe | Ketamin Inresa 2 ml, Fresenius Kabi Deutschland GmbH Isotone E NaCL 0.9, 26671.00.00, 6096595.00.00, Infusion, Ketamin Inresa 2 ml, Fresenius Kabi Deutschland GmbH Isotone E NaCL 0.9 | University Hospital Tuebingen, University Hospital Tuebingen | Males and females between 18-64 years with a diagnosis ofchronic depression, Males and females between 18-64 years with a diagnosis ofchronic depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000437-41: A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of Evenamide in patients with treatment-resistant schizophrenia (TRS). Studio multicentrico pilota, in aperto, randomizzato, per valutare sicurezza, tollerabilità ed efficacia preliminare in tre gruppi paralleli con tre dosi fisse di Evenamide somministrate come terapia aggiuntiva a pazienti affetti da schizofrenia resistente al trattamento (TRS). |
|
|
| Not yet recruiting | 2 | 150 | Europe | Evenamide, [NW-3509], Capsule, hard | NEWRON PHARMACEUTICALS SPA | Schizophrenia not responding adequately to current antipsychotic treatment Schizofrenia resistente al trattamento con una dose terapeutica stabile di un farmaco antipsicotico, Treatment-resistant schizophrenia (TRS) Schizofrenia trattamento-resistente (TRS), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-001980-95: OSU6162 in bipolar depression: an open-label, flexible dose study (OBID) |
|
|
| Not yet recruiting | 2 | 22 | Europe | OSU6162, OSU6162, Coated tablet | University of Gothenburg | Depression Bipolar disorder, Depression and Bipolar disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-001907-19: Pramipexole augmentation to target anhedonia in depression - a pilot study Tilläggsbehandling med Pramipexol mot anhedonisymptom vid depression - en pilotstudie |
|
|
| Not yet recruiting | 2 | 15 | Europe | Pramipexole Orion 0,26 mg, 0,52 mg, 1,05 mg and 2,1 mg, Prolonged-release tablet, Pramipexole Orion | Region Skåne, the Royal Physiographic Society of Lund, the Söderström-Königska Foundation, the province of Scania (Sweden) state grants (ALF), SUS Donations & Foundations | Depression, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000439-32: An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of Evenamide as add-on treatment in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their current antipsychotic medication. Studio di estensione in aperto, multicentrico per valutare sicurezza, tollerabilità ed efficacia preliminare a lungo termine di evenamide come terapia aggiuntiva in pazienti affetti da schizofrenia resistente al trattamento (TRS) che non rispondono adeguatamente al farmaco antipsicotico attualmente in corso |
|
|
| Not yet recruiting | 2 | 150 | Europe | Evenamide, [NW-3509], [NE-3509], Capsule, hard | NEWRON PHARMACEUTICALS SPA | Schizophrenia not responding adequately to current antipsychotic treatment Schizofrenia resistente al trattamento con una dose terapeutica stabile di un farmaco antipsicotico, Treatment-resistant schizophrenia (TRS) Schizofrenia trattamento-resistente (TRS), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-005860-69: OSU6162 as add-on in SSRI/SNRI-resistant depression (ODEN): a double-blind, placebo-controlled evaluation of efficacy and safety. |
|
|
| Not yet recruiting | 2 | 180 | Europe | OSU6162, Coated tablet | University of Gothenburg | Depression, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001278-44: Comparative analysis of the effectiveness of clozapine in resistant schizophrenia and schizoafective disorder. Análisis comparativo de la efectividad de la clozapina en esquizofreniaresistente y trastorno esquizoafectivo. |
|
|
| Ongoing | 2 | 120 | Europe | Clozapine, Tablet, Clozapine | Fundación Hospital Provincial de Castellón, Fundación Hospital Provincial de Castellón | Treatment-resistant schizophrenia and schizoafective disorder Esquizofrenia resistente al tratamiento y en trastorno esquizoafectivo, Treatment-resistant schizophrenia and schizoafective disorder, both are mental disorder. Esquizofrenia resistente al tratamiento y en trastorno esquizoafectivo, ambos enfermedades de salid mental., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-002813-20: A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder |
|
|
| Not yet recruiting | 2 | 240 | Europe | Brexpiprazole, OPC-34712, Tablet | Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | Borderline Personality Disorder, Borderline Personality Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-000350-26: A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLUTION study). Ensayo clÃnico para evaluar la eficacia de vafidemstat en sÃntomas negativos y deterioro cognitivo asociado a la esquizofrenia. (Estudio EVOLUTION). |
|
|
| Ongoing | 2 | 100 | Europe | Vafidemstat, ORY-2001, Capsule, hard | Oryzon Genomics, S.A., Oryzon Genomics, S.A. | Schizophrenia Esquizofrenia, Schizophrenia Esquizofrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-002905-24: Efficacy of ketamine nose-spray on acute suicidal thoughts and behaviou Effectiviteit van ketamine-neusspray op acute suïcidale gedachten engedrag |
|
|
| Ongoing | 2 | 112 | Europe | ketamine/ketalar, 1867-66-9, Nasal spray, solution | University Medical Center Groningen, ZonMw | Acute suicidality, which is a rapid increase in suicidal ideation orbehaviour from the patient's 'baseline' in the last 24 hours. Acute suïcidaliteit, gedefinieerd als een snelle toename in suïcidalegedachten of gedrag vanaf de 'baseline' van patiënt., Acute suicidality, thoughts about the wish to kill oneself, or behaviour with either the aim to die or a significant likelyhood that one could die because of this behaviour Acute suïcidaliteit, gedachten over de wens zichzelf van het leven tewillen beroven, of gedrag met het doel te sterven of met een grotewaarschijnlijkheid dat men als gevolg van het gedrag sterft., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Not yet recruiting | 2 | 111 | Europe | Fluoxetin, Capsule, Fluoxetine | Karolinska Universitetssjukhuset, SLSO Stockholm | Pedophilic Disorder, Pedofil störning, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003421-28: Ketamine interleaved with electroconvulsive therapy for depression, a pragmatic randomised controlled pilot trial (KITE-Dep) |
|
|
| Not yet recruiting | 2 | 24 | Europe | Ketalar 10mg/ml Solution for injection, Hypnovel 10mg/5ml solution for injection, N01AX03, Solution for injection/infusion, Solution for infusion, Ketalar, Hypnovel 10mg/5ml solution for injection | St Patrick's Mental Health Services, none | Depression, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-004752-16: A Study to Evaluate the Effects of RO6889450 (Ralmitaront) in Patients with Schizophrenia or Schizoaffective Disorder and Negative Symptoms Estudio para evaluar los efectos de RO6889450 (Ralmitaront) en pacientes con esquizofrenia o trastorno esquizoafectivo y síntomas negativos |
|
|
| Ongoing | 2 | 220 | Europe, RoW | ralmitaront, RO6889450, Capsule, hard | F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd | Schizophrenia or schizoaffective disorder esquizofrenia o trastorno esquizoafectivo, Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia may result in hallucinations, delusions, and disordered behavior that impairs daily functioning Esquizofrenia: trastorno mental grave en el que las personas interpretan la realidad de forma anormal y puede resultar en alucinaciones, delirios y comportamiento desordenado que afecta el func diario, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-005037-32: Psilocybin - a strategy of rapid antidepressant response in depression comorbid with cancer. Psilocybin – strategie rychlé antidepresivní odpovědi u deprese komorbidní s onkologickým onemocněním. |
|
|
| Not yet recruiting | 2 | 60 | RoW | Psilocybine, ketamine hydrochloride, MIDAZOLAM, Capsule, hard | Národní ústav duševního zdraví, Národní ústav duševního zdraví | Depressive disorder comorbid with cancer Depresivní porucha komorbidní s onkologickým onemocněním, Depressive disorder accompanying cancer Depresivní porucha provázející onkologické onemocnění, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-002577-22: The safety and efficacy of psilocybin as an adjunctive therapy in participants with treatment-resistant depression |
|
|
| Not yet recruiting | 2 | 20 | Europe | Psilocybin 5 mg, Capsule | COMPASS Pathfinder, Limited, COMPASS Pathfinder, Limited | treatment resistant depression, treatment resistant depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-000867-65: Investigation of the adhesion properties of a newly developed rotigotine-containing patch in patients with Parkinson's disease |
|
|
| Not yet recruiting | 2 | 38 | Europe | ROT-TDS 8 mg/24 h, Neupro® 8 mg/24 h, Transdermal patch, Neupro® 8 mg/24 h | Luye Pharma Switzerland AG, Luye Pharma Switzerland AG | Idiopathic Parkinson's disease, Idiopathic Parkinson's disease, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-003851-41: A Treatment Study with Bumetanide (a diuretic) aimed for Children with Autism En Behandlingsstudie med Bumetanide (ett diuretikum) riktad till Barn med Autism |
|
|
| Ongoing | 2 | 30 | Europe | Burinex, 00289/0322, Tablet, Burinex | Gillberg Neuropsychiatry Centre, Gillberg Neuropsychiatry Centre | Autism spectrum disorder, a neurodevelopmental disorder with onset in childhood.The disorder implies deficits in social and communicative abilities and restricted interests and behaviors. Many children with autism also have other coexisting disorders, such as intellectual disability. Autism, en utvecklingsneurologisk funktionsnedsättning, som innebär nedsatt social och kommunikativ förmåga samt begränsade beteenden och intressen. Många barn med autism har samtidigt andra funktionsnedsättningar som intellektuell funktionsnedsättning., Autism is a neurodevelopmental disorder that affects about one percent of children.Symptoms may be apparent during the first years of life, but sometimes symptoms are not evident until school age. Autism är en utvecklingsneurologisk funktionsnedsättning som innefattar brister i social och kommunikativ förmåga samt begränsade beteende och intressen. Autism förekommer hos drygt 1% av barn., Psychiatry and Psychology [F] - Behaviours [F01] | | | | |
2021-000805-26: MDMA-Assisted Psychotherapy for the Treatment of Depression |
|
|
| Not yet recruiting | 2 | 12 | Europe | 3,4-methylenedioxymethamphetamine hydrochloride/MDMA HCl /Capsule Active substance: 42542-10-9/3,4-M, Capsule | Østfold Hospital Trust, South-Eastern Norway Regional Health Authority, MAPS PBC | Major Depressive Disorder, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-000319-21: Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial)” |
|
|
| Not yet recruiting | 2 | 189 | Europe | Clonidinhydrochlorid, Doxazosinmesilat, Capsule, hard, Clonidin-ratiopharm® 75, Doxazosin STADA® 1mg Tabletten, Doxacor® 2 mg, Tabletten | Charité – Universitätsmedizin Berlin, Federal Ministry of Education and Research (BMBF) | Posttraumatic Stress Disorder Posttraumatische Belastungsstörung, Posttraumatic Stress Disorder Posttraumatische Belastungsstörung, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-003369-16: An irregular trial in which the identity of those receiving the intervention in twin groups is concealed from both the administrators and subject until the test is completed. The trial is to check the safety and efficacy of GWP42003-P versus Placebo as a joining therapy in Participants with Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment. Un ensayo irregular en el que la identidad de quienes reciben la intervención en grupos gemelos se oculta tanto a los administradores como al sujeto hasta que se completa la prueba.El estudio es para investigar la seguridad y la eficacia de GWP42003-P frente a placebo como tratamiento complementario en participantes con esquizofrenia que experimenten respuesta inadecuada al tratamiento con antipsicóticos en curso. |
|
|
| Not yet recruiting | 2 | 366 | Europe | Cannabidiol (CBD), GWP42003-P, Oral solution, CBD-Oral Solution, is known as Epidyolex, and is the approved name in the EU | GW Research Ltd., GW Research Ltd | Schizophrenia is neurodevelopmental syndrome, results from gradual alterations in brain connectivity. Can persist for years before psychosis emerges. Individuals have a 2 to 3 fold increased risk of death from a range of comorbid somatic conditions and suicide, the former attributable to unhealthy lifestyle, predisposition, and antipsychotic medication. Individuals typically smoke, can be overweight or obese, suffer from hypertension, dyslipidemias, metabolic syndrome, and diabetes. Esquizofrenia es un síndrome del neurodesarrollo resultado de alteraciones graduales en la conectividad cerebral.Puede persistir durante años antes de que surja la psicosis.El riesgo de muerte es de 2 a 3 veces mayor debido a una variedad de afecciones somáticas comórbidas y suicidio,el primero atribuible a un estilo de vida poco saludable,predisposición y medicamentos antipsicóticos. Las personas suelen fumar,tener sobrepeso u obesidad, hipertensión,dislipidemias,síndrome metabólico ydiabetes, schizophrenia is a severe long-term mental health condition. It causes a range of different psychological symptoms. La esquizofrenia es una afección grave de salud mental a largo plazo. Causa una variedad de síntomas psicológicos diferentes, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Completed | 2 | 90 | RoW | Probiotics C2P | National Institute of Mental Health, Czech Republic, C2P s.r.o., University Hospital Vinohrady, Ministry of Industry and Trade, Czech Republic | Memory Deficits, Mood Change, Gut Health, Aging Problems, Aging, Cognitive Decline | 03/22 | 03/22 | | |
2021-001839-77: Efficacy and saefety of Perampanel on behaviour and quality of life in Patients with POGZ-Related Disorder Efficacia e sicurezza del Perampanel sul comportamento e la qualità di vita nei pazienti con sindrome POGZ |
|
|
| Not yet recruiting | 2 | 40 | Europe | Fycompa, perampanel, [042581037], [n.a.], Coated tablet | IRCCS MATERNO INFANTILE BURLO GAROFOLO, IRCCS materno infantile Burlo Garofolo | Patients with POGZ related disorder Pazienti con varianti patogenetiche/verosimilmente patogenetiche nel gene POGZ, Patients with neurodevelopmental disorder characterized by intellectual disability and/or autism and malformations in different organs of genetic origin Pazienti con disordini del neurosviluppo caratterizzato da disabilità intellettiva e/o autismo e malformazioni in vari organi di origine monogenica, Diseases [C] - Symptoms and general pathology [C23] | | | | |
2021-004790-31: A Clinical Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression Estudio para analizar la eficacia, la seguridad y la tolerabilidad de JNJ-55308942 en el tratamiento de la depresión bipolar |
|
|
| Ongoing | 2 | 164 | Europe | JNJ-55308942, JNJ-55308942, Capsule | Janssen-Cilag International NV, Janssen Research & Development, LLC | Bipolar Depression Depresión Bipolar, Depression Depresión, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-003164-27: Evaluation of Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients Evaluatie van veiligheid, farmacodynamiek en farmacokinetiek van TW001 in Alzheimer patiënten |
|
|
| Ongoing | 2 | 150 | Europe | TW001 granules for oral solution, TEST, Granules for oral solution | Treeway TW001AD B.V., Treeway TW001AD B.V. | Alzheimer´s Disease (AD) Ziekte van Alzheimer, Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills, and, eventually, the ability to carry out the simplest tasks. De ziekte van Alzheimer is een hersenaandoening die langzaam het geheugen en de denkvaardigheden vernietigt, en uiteindelijk het vermogen om de eenvoudigste taken uit te voeren., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-006861-39: A Phase 2 Clinical Trial of GH001 in Patients with Bipolar II Disorder and a Current Major Depressive Episode |
|
|
| Not yet recruiting | 2 | 15 | Europe | 5-MeO-DMT 6,12 and 18mg powder in vial for reconstitution, GH001, Inhalation vapour, solution | GH Research Ireland Limited, GH Research Ireland Limited | Bipolar II Disorder, Form of mental illness where patients experience major depressive episodes and at least one hypomania episode., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-004548-31: CLINICAL TRIAL TO EVALUATE THE ANTIDEPRESSANT EFFICACY OF PSYCHOTHERAPY AND CITALOPRAM IN WOMEN DIAGNOSED WITH BREAST CANCER AND MAJOR DEPRESSION ENSAYO CLÍNICO PARA EVALUAR LA EFICACIA ANTIDEPRESIVA DE LA PSICOTERAPIA Y DEL CITALOPRAM EN MUJERES DIAGNOSTICADAS DE CÁNCER DE MAMA Y DEPRESIÓN MAYOR |
|
|
| Not yet recruiting | 2 | 40 | Europe | Citalopram, Tablet, PRISDAL 20mg PRISDAL 30mg | Cinto Segalàs, Asociación Española Contra El Cáncer | Female patients diagnosed with breast cancer who, during the first year following the diagnosis of oncological disease, have affective symptomatology that meets DSM-V criteria for major depression. Pacientes mujeres diagnosticadas de cáncer de mama que a lo largo del primer año tras el diagnóstico de la enfermedad oncológica presentan sintomatología afectiva que cumple criterios DSM-V de depresión mayor., Breast cancer and major depression disease. Cáncer de mama y depresión mayor., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
CLIN-011, NCT04739423: A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders |
|
|
| Active, not recruiting | 2 | 41 | Europe, RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia | 07/22 | 07/23 | | |
2021-006879-42: A phase 2 clinical trial of GH001 in patients with postpartum depression |
|
|
| Not yet recruiting | 2 | 15 | Europe | 5-MeO-DMT 6, 12, 18mg, powder in vial for reconstitution, GH001, Inhalation vapour, solution | GH Research Ireland Limited, GH Research Ireland Limited | Post-Partum Depression, Depression associated with pregnancy and childbirth, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-005596-39: Long-term follow-up of safety and effectiveness of MDMA-assisted therapy for posttraumatic stress disorder Dlouhodobé sledování bezpečnosti a persistence MDMA-asistované terapie k léčbě posttraumatické stresové poruchy |
|
|
| Not yet recruiting | 2 | 37 | RoW | 3,4- methylenedioxymethamphetamine hydrochloride, MDMA HCI, Capsule | MAPS Europe B.V., MAPS Europe B.V. | post-traumatic stress disorder (PTSD) Posttraumatická stresová porucha (PTSP), post-traumatic stress disorder, PTSD, Trauma Posttraumatická stresová porucha, PTSP, Trauma, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-006200-33: A Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults with Alcohol Use Disorder (AUD) Kliininen tutkimus, jossa arvioidaan psilosybiiniavusteisen psykoterapian tehokkuutta ja turvallisuutta aikuisilla, joilla on alkoholinkäytön häiriö (AUD) |
|
|
| Not yet recruiting | 2 | 160 | Europe | Psilocybin capsule 25 mg, Capsule | Clairvoyant Therapeutics Inc., Clairvoyant Therapeutics Inc. | Alcohol use disorder (AUD), Alcohol use disorder (AUD), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000580-52: A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia |
|
|
| Not yet recruiting | 2 | 600 | Europe | Emraclidine, CVL-231, Tablet | Cerevel Therapeutics, LLC, Cerevel Therapeutics, LLC | Patients with schizophrenia who are experiencing an acute exacerbation of psychosis, Schizophrenia is mental disorder that exhibits problems with positive symptoms (e.g. hallucinations), negative symptoms (e.g. lack of motivation) and cognitive deficits (e.g. information processing)., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-005457-25: Study to assess the safety and efficacy of PCN-101 in treatment-resistant depression |
|
|
| Not yet recruiting | 2 | 93 | Europe | R-ketamine hydrochloride, PCN-101, Concentrate for solution for infusion | Perception Neuroscience, Inc, Perception Neuroscience, Perception Neuroscience, Inc. | Treatment-resistant depression, Treatment-resistant depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 2 | 60 | RoW | Ketamin Inresa 10 ml Solution for injection 500 mg 50 mg/ml, Solution for injection, Ketamin Inresa 10 ml Solution for injection 500 mg 50 mg/ml | University of Cyprus, Research and Innovation Foundation | Methadone and buprenorphine comprise a first-line, evidence-based opioid substitution treatment (OST) for OUD patients. Unfortunately, retention and adherence to OST treatment is currently a major challenge in the treatment of OUDs. Another major challenge for opioid addicts who are recovering from addiction is the maintenance of a drug-free state due to the negative affect associated with protracted opioid abstinence, including depression, anhedonia, and anxiety., Opioid addiction is a chronic, relapsing brain disorder causing high rates of mortality, primarily due to overdose incidences., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000574-26: A randomized, double-blind, placebo-controlled, Phase 2b trial of GH001 in patients with treatment resistant depression |
|
|
| Not yet recruiting | 2 | 80 | Europe, RoW | GH001, GH001, Inhalation vapour, liquid | GH Research Ireland Limited, GH Research Ireland Ltd. | Treatment-resistant depression (TRD), Depression that has not improved with other treatments., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-006773-38: TSPO ligands in the treatment of depression TSPO-Liganden in der Depressionsbehandlung |
|
|
| Not yet recruiting | 2 | 50 | Europe | Etifoxine, 7560/2006/01-02, Capsule, hard, Stresam | Medizinische Einrichtungen des Berzirks Oberpfalz, Deutsche Forschungsgemeinschaft | Unipolar/bipolar depressive disorder Unipolare/bipolare Depression, Depressive disorder Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-002462-32: Pilot study on the safety and feasibility of intravenous opioid substitution-based therapy with Hydagelan® (hydromorphone hydrochloride) in Vienna. Pilotstudie zur Sicherheit und Machbarkeit einer intravenösen Substitutionstherapie mit Hydagelan® (Hydromorphonhydrochlorid) in Wien |
|
|
| Not yet recruiting | 2 | 30 | Europe | Solution for injection/infusion, Hydagelan | Suchthilfe Wien gGmbH, Suchthilfe Wien gGmbH, G.L. Pharma GmbH | Opioid dependence: Opioid dependence is a serious and usually chronic disease that requires treatment, encompasses various psychological and physical dimensions, and is associated with concomitant diseases and increased mortality. Opioidabhängigkeit: Opioidabhängigkeit ist eine behandlungsbedürftige, schwere und meist chronisch verlaufende Erkrankung, die verschiedene psychische und physische Dimensionen umfasst und mit Begleiterkrankungen sowie erhöhter Mortalität verbunden ist., Opioid dependence is a severe and usually chronic disease requiring treatment. Opioidabhängigkeit ist eine schwere und zumeist chronische und behandlungsbedürftige Erkrankung., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
